Ongoing Clinical Trials

Advanced Breast Cancer

BriaCell is conducting a Phase I/II clinical trial of Bria-IMT™, BriaCell’s lead candidate, in combination with the immunotherapy development candidates retifanlimab (INCMGA00012), an anti-PD-1 antibody (provided by Incyte). The combination study is listed on ClinicalTrials.gov as NCT03328026.

Patients are encouraged to contact Trialjectory to determine eligibility for participation in the clinical study.